5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.

[1]  Laura E. Pascal,et al.  Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research , 2014, Asian journal of andrology.

[2]  L. Mearini.  Re: A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″. , 2014, International braz j urol : official journal of the Brazilian Society of Urology.

[3]  C. Konstantinidis,et al.  A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″. , 2014, International braz j urol : official journal of the Brazilian Society of Urology.

[4]  R. Vessella,et al.  5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. , 2013, Endocrinology.

[5]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[6]  T. Kuzel,et al.  Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Charles A Enke,et al.  Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Fred Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[9]  M. Aapro,et al.  Improving the management of patients with prostate cancer receiving long‐term androgen deprivation therapy , 2012, BJU international.

[10]  M. Lucia,et al.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[11]  L. Gomella,et al.  Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach? , 2011, Current urology reports.

[12]  S. Goldenberg,et al.  Intermittent androgen suppression for prostate cancer , 2010, Nature Reviews Urology.

[13]  J. Nelson,et al.  Prolongation of off‐cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model , 2009, The Prostate.

[14]  N. Spry,et al.  Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. , 2006, European journal of cancer.

[15]  C. Higano,et al.  Intermittent androgen deprivation: clinical experience and practical applications. , 2006, The Urologic clinics of North America.

[16]  R. Jennrich,et al.  Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. , 2006, The Journal of urology.

[17]  S. Eggener,et al.  Enhancement of intermittent androgen ablation by “off‐cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model , 2006, The Prostate.

[18]  A. De la taille,et al.  Intermittent androgen suppression in patients with prostate cancer , 2003, BJU international.

[19]  X. Cai,et al.  Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. , 2001, Gene expression.

[20]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. , 2000, Molecular urology.

[21]  J. Crook,et al.  Intermittent androgen suppression in the management of prostate cancer. , 1999, Urology.

[22]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[23]  M. Gleave,et al.  Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience , 1998, European Urology.

[24]  M. Gleave,et al.  Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  Nicholas Bruchovsky,et al.  Control of tumor progression by maintenance of apoptosis , 1996, The Prostate. Supplement.

[26]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[27]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[28]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[29]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[30]  D. Euhus,et al.  Tumor measurement in the nude mouse , 1986, Journal of surgical oncology.